« Return to News | Drug Sponsors

EMD Millipore inks exclusive agreement with Julphar Diabetes for insulin

Wednesday, August 8, 2012 11:02 AM

EMD Millipore, the life science division of Merck KGaA, has announced an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates.

The insulin is of non-animal origin and will be marketed under EMD Millipore’s CellPrime brand name, complementing the company’s range of non-animal origin supplements for cell culture biomanufacturing.

“CellPrime Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety,” said Burghard Freiberg, senior vice president of pharm chemicals solutions. “Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective.”

EMD Millipore chose Julphar Diabetes as its source for recombinant human insulin because the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.